ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
NCT ID: NCT00936676
Last Updated: 2016-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
684 participants
OBSERVATIONAL
2009-07-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial
NCT01709461
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
NCT01049984
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
NCT01055379
Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease
NCT01048229
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT05116813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rasagiline mesylate
Enrollment by invitation to participates from the ADAGIO trial
rasagiline mesylate
During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rasagiline mesylate
During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who are currently on rasagiline treatment (or subjects who have stopped rasagiline treatment, are willing to restart treatment, and in the opinion of the investigator will gain clinical benefit from restarting treatment) and
3. Subjects with a diagnosis of Parkinson's disease and
4. Subjects willing and able to give written informed consent
Exclusion Criteria
2. Subjects who cannot be given rasagiline due to any exclusion based on the local label (including pregnancy or nursing women) or due to the use of medications contraindicated for concomitant use with rasagiline according to local label
3. Subjects with a medical condition that is considered by the investigator as significant enough to prevent participation
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Neuroscience, Inc.
INDUSTRY
H. Lundbeck A/S
INDUSTRY
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
C Warren Olanow, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Department of Neurology, Mount Sinai School of Medicine
Olivier Rascol, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, Toulouse, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teva Investigational Site 7054
Birmingham, Alabama, United States
Teva Investigational Site 7006
Tucson, Arizona, United States
Teva Investigational Site 7018
Irvine, California, United States
Teva Investigational Site 7019
La Jolla, California, United States
Teva Investigational Site 7039
Loma Linda, California, United States
Teva Investigational Site 7023
Los Angeles, California, United States
Teva Investigational Site 7022
Sunnyvale, California, United States
Teva Investigational Site 7024
Danbury, Connecticut, United States
Teva Investigational Site 7016
Farmington, Connecticut, United States
Teva Investigational Site 7020
Boca Raton, Florida, United States
Teva Investigational Site 7011
Gainesville, Florida, United States
Teva Investigational Site 7045
Miami, Florida, United States
Teva Investigational Site 7017
Tampa, Florida, United States
Teva Investigational Site 7055
Atlanta, Georgia, United States
Teva Investigational Site 7043
Augusta, Georgia, United States
Teva Investigational Site 7013
Chicago, Illinois, United States
Teva Investigational Site 7052
Chicago, Illinois, United States
Teva Investigational Site 7001
Northbrook, Illinois, United States
Teva Investigational Site 7008
Springfield, Illinois, United States
Teva Investigational Site 7037
Des Moines, Iowa, United States
Teva Investigational Site 7053
Scarborough, Maine, United States
Teva Investigational Site 7026
Boston, Massachusetts, United States
Teva Investigational Site 7015
Lansing, Michigan, United States
Teva Investigational Site 7010
Traverse City, Michigan, United States
Teva Investigational Site 7029
Golden Valley, Minnesota, United States
Teva Investigational Site 7004
Omaha, Nebraska, United States
Teva Investigational Site 7046
Buffalo, New York, United States
Teva Investigational Site 7048
Durham, North Carolina, United States
Teva Investigational Site 7051
Raleigh, North Carolina, United States
Teva Investigational Site 7034
Cincinnati, Ohio, United States
Teva Investigational Site 7009
Toledo, Ohio, United States
Teva Investigational Site 7002
Allentown, Pennsylvania, United States
Teva Investigational Site 7044
Philadelphia, Pennsylvania, United States
Teva Investigational Site 7050
Providence, Rhode Island, United States
Teva Investigational Site 7035
Houston, Texas, United States
Teva Investigational Site 7056
Houston, Texas, United States
Teva Investigational Site 7025
Milwaukee, Wisconsin, United States
Teva Investigational Site 7160
Buenos Aires, , Argentina
Teva Investigational Site 7161
Buenos Aires, , Argentina
Teva Investigational Site 7162
Buenos Aires, , Argentina
Teva Investigational Site 7163
Buenos Aires, , Argentina
Teva Investigational Site 7164
Pilar - Buenos Aires, , Argentina
Teva Investigational Site 7088
Calgary, Alberta, Canada
Teva Investigational Site 7086
Winnipeg, Manitoba, Canada
Teva Investigational Site 7085
Halifax, Nova Scotia, Canada
Teva Investigational Site 7083
London, Ontario, Canada
Teva Investigational Site 7087
Markham, Ontario, Canada
Teva Investigational Site 7089
Toronto, Ontario, Canada
Teva Investigational Site 7081
Montreal, Quebec, Canada
Teva Investigational Site 7080
Québec, Quebec, Canada
Teva Investigational Site 7082
Saskatoon, Saskatchewan, Canada
Teva Investigational Site 7201
Aix-en-Provence, , France
Teva Investigational Site 7202
Clermont-Ferrand, , France
Teva Investigational Site 7203
Créteil, , France
Teva Investigational Site 7204
Lille, , France
Teva Investigational Site 7206
Nantes, , France
Teva Investigational Site 7205
Pessac, , France
Teva Investigational Site 7200
Toulouse, , France
Teva Investigational Site 7304
Bochum, , Germany
Teva Investigational Site 7309
Düsseldorf, , Germany
Teva Investigational Site 7306
Erbach im Odenwald, , Germany
Teva Investigational Site 7303
Gera, , Germany
Teva Investigational Site 7307
Kassel, , Germany
Teva Investigational Site 7300
Kiel, , Germany
Teva Investigational Site 7308
Tübingen, , Germany
Teva Investigational Site 7302
Ulm, , Germany
Teva Investigational Site 7400
Budapest, , Hungary
Teva Investigational Site 7401
Budapest, , Hungary
Teva Investigational Site 7404
Debrecen, , Hungary
Teva Investigational Site 7501
Ramat Gan, IL, Israel
Teva Investigational Site 7502
Beersheba, , Israel
Teva Investigational Site 7504
Haifa, , Israel
Teva Investigational Site 7507
Haifa, , Israel
Teva Investigational Site 7505
Jerusalem, , Israel
Teva Investigational Site 7506
Petah Tikva, , Israel
Teva Investigational Site 7503
Ramat Gan, , Israel
Teva Investigational Site 7500
Tel Aviv, , Israel
Teva Investigational Site 7604
Grosseto, , Italy
Teva Investigational Site 7600
Lido Di Camaiore (Lucca), , Italy
Teva Investigational Site 7602
Milan, , Italy
Teva Investigational Site 7607
Milan, , Italy
Teva Investigational Site 7610
Parma, , Italy
Teva Investigational Site 7601
Pozzilli (IS), , Italy
Teva Investigational Site 7606
Roma, , Italy
Teva Investigational Site 7611
Roma, , Italy
Teva Investigational Site 7615
Roma, , Italy
Teva Investigational Site 7704
Blaricum, , Netherlands
Teva Investigational Site 7150
Lisbon, , Portugal
Teva Investigational Site 7100
Bucharest, , Romania
Teva Investigational Site 7102
Cluj-Napoca, , Romania
Teva Investigational Site 7104
Constanța, , Romania
Teva Investigational Site 7103
Târgu Mureş, , Romania
Teva Investigational Site 7101
Timișoara, , Romania
Teva Investigational Site 7800
Barcelona, , Spain
Teva Investigational Site 7801
Barcelona, , Spain
Teva Investigational Site 7802
Barcelona, , Spain
Teva Investigational Site 7806
Bilbao, , Spain
Teva Investigational Site 7803
Donostia / San Sebastian, , Spain
Teva Investigational Site 7804
L'Hospitalet de Llobregat, , Spain
Teva Investigational Site 7805
Madrid, , Spain
Teva Investigational Site 7902
Cambridge, , United Kingdom
Teva Investigational Site 7900
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-011541-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
TVP-1012/501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.